Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating ...

Ab­b­Vie and San­doz have re­solved their patent dis­pute over Ab­b­Vie’s block­buster im­munol­o­gy drug Rin­voq. San­doz ...

AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell ...

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While ...

The European Commission (“EC”) granted marketing approval to AbbVie’s Rinvoq for treating giant cell arteritis (“GCA”), an ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

The drug-funding agency estimated that 1200 patients would benefit this year, rising to more than 5000 annually after 2030.

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...